Working... Menu

Linagliptin's Effect on CD34+ Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02467478
Recruitment Status : Recruiting
First Posted : June 10, 2015
Last Update Posted : August 7, 2018
Boehringer Ingelheim
Information provided by (Responsible Party):
Sabyasachi Sen, George Washington University

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 2019
  Estimated Study Completion Date : December 2019